FY2025 · period end Dec '25 · from the 10-K filed Feb 20, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B |
| Gross Profit | $42.96B | $39.43B | $33.90B | $40.64B | $38.75B |
| Operating Income | $15.07B | $9.14B | $12.76B | $18.12B | $17.92B |
| Net Income | — | $4.28B | $4.86B | $11.84B | $11.54B |
| EPS (Diluted) | — | $2.39 | $2.72 | $6.63 | $6.45 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $133.96B | $135.16B | $134.71B | $138.81B | $146.53B |
| Total Liabilities | — | — | — | — | — |
| Stockholders' Equity | negative: -$3.23B | $3.36B | $10.40B | $17.29B | $15.44B |
| Cash & Equivalents | $5.23B | $5.52B | $12.81B | $9.20B | $9.75B |
| Total Debt | $58.94B | $60.34B | $52.19B | $59.13B | $64.19B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $19.03B | $18.81B | $22.84B | $24.94B | $22.78B |
| Capital Expenditures | $1.21B | $0.97B | $0.78B | $0.69B | $0.79B |
| Free Cash Flow | $17.82B | $17.83B | $22.06B | $24.25B | $21.99B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 70.2% | 70.0% | 62.4% | 70.0% | 69.0% |
| Operating Margin | 24.6% | 16.2% | 23.5% | 31.2% | 31.9% |
| Net Margin | — | 7.6% | 9.0% | 20.4% | 20.5% |
| Return on Equity | — | 127.2% | 46.8% | 68.5% | 74.8% |
| Return on Assets | — | 3.2% | 3.6% | 8.5% | 7.9% |
| Debt / Equity | negative: -18.26× | 17.94× | 5.02× | 3.42× | 4.16× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001104659-26-098367 | Aug 18, 2026 | Aug 18, 2026 | Aug 18, 2026 20:30 UTC | EDGAR |
| 8-K | 0001104659-26-091269 | Aug 4, 2026 | Aug 5, 2026 | Aug 5, 2026 21:17 UTC | EDGAR |
| 10-Q | 0001551152-26-000026 | Jun 30, 2026 | Aug 3, 2026 | Aug 3, 2026 18:14 UTC | EDGAR |
| 8-K | 0001551152-26-000023 | Jul 31, 2026 | Jul 31, 2026 | Jul 31, 2026 11:51 UTC | EDGAR |
| 8-K | 0001551152-26-000021 | Jul 6, 2026 | Jul 6, 2026 | Jul 6, 2026 20:12 UTC | EDGAR |
| 8-K | 0001104659-26-076067 | Jun 18, 2026 | Jun 22, 2026 | Jun 22, 2026 11:11 UTC | EDGAR |
| 8-K | 0001104659-26-059484 | May 8, 2026 | May 12, 2026 | May 12, 2026 21:01 UTC | EDGAR |
| 10-Q | 0001551152-26-000017 | Mar 31, 2026 | May 8, 2026 | May 8, 2026 16:28 UTC | EDGAR |
Direct links to SEC EDGAR. ABBV has additional filings available on the SEC site.
Who is buying and selling AbbVie Inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on ABBV yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on ABBV and publish the result to your public profile.
Ask about AbbVie Inc.
Continue in Workspace — cited answers on ABBV, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs